DiaMedica Therapeutics (DMAC) Change in Receivables (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Change in Receivables of $43000.0 for Q1 2026, up 152.94% year-over-year from $17000.0 in Q1 2025, and up 2250.0% quarter-over-quarter from -$2000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Change in Receivables (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Change in Receivables history runs 9 years deep, the most recent figure standing at $43000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 152.94% year-over-year to $43000.0; the TTM figure through Mar 2026 stood at $48000.0 (up 132.88% YoY), while the FY2025 annual figure was $22000.0, up 116.54% from the prior year.
- Change in Receivables for Q1 2026 stood at $43000.0, up from -$2000.0 in the prior quarter.
- The five-year high for Change in Receivables was $131000.0 in Q2 2023, with the low at -$101000.0 in Q3 2024.
- The 5-year median for Change in Receivables is $7000.0 (2022), against an average of $10058.8.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables surged 1366.67% in 2022, then slumped 1050.0% in 2025.
- DiaMedica Therapeutics' Change in Receivables stood at $7000.0 in 2022, then soared by 742.86% to $59000.0 in 2023, then tumbled by 191.53% to -$54000.0 in 2024, then jumped by 96.3% to -$2000.0 in 2025, then surged by 2250.0% to $43000.0 in 2026.
- Business Quant data shows DMAC's Change in Receivables at $43000.0 in Q1 2026, -$2000.0 in Q4 2025, and $99000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -57,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57,000.00 |
| Jun 30, 2026 | -57,000.00 |
| Mar 31, 2026 | 43,000.00 |
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Jun 30, 2025 | -92,000.00 |
| Jun 30, 2025 | -92,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | -54,000.00 |
| Dec 31, 2024 | -54,000.00 |
| Sep 30, 2024 | -101,000.00 |
| Sep 30, 2024 | -101,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |